Display options
Cite
Baba Y, Fujii M, Tokumaru Y, et al. Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. J Oncol. 2012;2012:986725doi: 10.1155/2012/986725.
Baba, Y., Fujii, M., Tokumaru, Y., & Kato, Y. (2012). Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. Journal of oncology, 2012986725. https://doi.org/10.1155/2012/986725
Baba, Yuh, et al. "Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer." Journal of oncology vol. 2012 (2012): 986725. doi: https://doi.org/10.1155/2012/986725
Baba Y, Fujii M, Tokumaru Y, Kato Y. Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. J Oncol. 2012;2012:986725. doi: 10.1155/2012/986725. Epub 2012 Mar 26. PMID: 22545054; PMCID: PMC3321461.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2012;2012:986725. doi: 10.1155/2012/986725. Epub 2012 Mar 26.

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Journal of oncology

Yuh Baba, Masato Fujii, Yutaka Tokumaru, Yasumasa Kato

Affiliations

  1. Department of Otorhinolaryngology and Head and Neck Surgery, Ohtawara Red Cross Hospital, 2-7-3, Sumiyoshi-cho, Ohtawara City, Tochigi 324-8686, Japan.

PMID: 22545054 PMCID: PMC3321461 DOI: 10.1155/2012/986725

Abstract

Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely rare, monotherapy with EGFR inhibitors has shown limited success. The PI3kinase/Akt pathway is responsible for cellular survival, and inhibition of phosphatidylinositol (PI) synthesis has antiproliferative, anti-invasive, and antiangiogenesis effects on HNSCC. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway in HNSCC, as has molecular crosstalk between the NFκB and STAT3 signaling pathways. Therefore, the combination of an EGFR antagonist with an agent that inhibits the activation of both Akt and NFκB may overcome resistance to EGFR antagonists in HNSCC.

References

  1. Eur J Cancer. 2003 Jul;39(10):1348-54 - PubMed
  2. Cancer Res. 2007 Apr 15;67(8):3626-36 - PubMed
  3. Angiogenesis. 2010 Mar;13(1):1-14 - PubMed
  4. Int J Biochem Cell Biol. 2007;39(7-8):1349-57 - PubMed
  5. Semin Oncol. 2000 Aug;27(4 Suppl 8):25-33 - PubMed
  6. Clin Exp Metastasis. 2004;21(5):419-25 - PubMed
  7. Int J Cancer. 1995 Aug 22;64(4):280-5 - PubMed
  8. Eur J Cancer. 2006 Jan;42(1):109-11 - PubMed
  9. Clin Cancer Res. 2002 Mar;8(3):885-92 - PubMed
  10. Nat Genet. 1999 Jan;21(1):99-102 - PubMed
  11. Clin Cancer Res. 2007 Jul 15;13(14):4291-9 - PubMed
  12. J Clin Oncol. 2006 Jan 10;24(2):306-14 - PubMed
  13. Cancer Lett. 2007 Apr 18;248(2):269-79 - PubMed
  14. Recent Results Cancer Res. 2000;157:90-106 - PubMed
  15. Expert Opin Investig Drugs. 2009 Dec;18(12):1829-42 - PubMed
  16. Neoplasia. 2006 Sep;8(9):733-46 - PubMed
  17. Clin Cancer Res. 2004 Nov 15;10(22):7764-74 - PubMed
  18. Nat Cell Biol. 2007 Mar;9(3):316-23 - PubMed
  19. J Clin Oncol. 2005 Sep 1;23(25):5900-9 - PubMed
  20. Oncol Rep. 2008 Jan;19(1):65-71 - PubMed
  21. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3636-41 - PubMed
  22. Lung Cancer. 2008 Jun;60 Suppl 2:S10-8 - PubMed
  23. Br J Cancer. 2006 Jul 17;95(2):172-80 - PubMed
  24. Curr Opin Genet Dev. 2009 Feb;19(1):12-7 - PubMed
  25. N Engl J Med. 2001 Dec 27;345(26):1890-900 - PubMed
  26. Oncogene. 1999 Apr 1;18(13):2221-30 - PubMed
  27. Mol Cancer Ther. 2007 Sep;6(9):2449-57 - PubMed
  28. Mol Cancer Ther. 2006 Oct;5(10):2494-502 - PubMed
  29. Urology. 2007 Mar;69(3):596-602 - PubMed
  30. Mol Cell. 2007 Mar 23;25(6):917-31 - PubMed
  31. Cancer Sci. 2009 Nov;100(11):2202-9 - PubMed
  32. Science. 2004 Aug 20;305(5687):1163-7 - PubMed
  33. J Clin Oncol. 2004 Jan 1;22(1):77-85 - PubMed
  34. Mol Cancer Ther. 2005 Sep;4(9):1349-57 - PubMed
  35. Curr Oncol. 2010 Jun;17(3):37-48 - PubMed
  36. Oncogene. 1998 Sep 24;17(12):1557-65 - PubMed
  37. J Cell Biol. 2004 Jul 19;166(2):213-23 - PubMed
  38. Arch Otolaryngol Head Neck Surg. 2000 Aug;126(8):957-61 - PubMed
  39. Mol Cancer Ther. 2007 Jun;6(6):1683-91 - PubMed
  40. Clin Exp Metastasis. 2000;18(3):273-9 - PubMed
  41. Prostate. 2006 Jun 15;66(9):895-902 - PubMed
  42. Int J Oncol. 2011 Jan;38(1):189-200 - PubMed
  43. Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):139-43 - PubMed
  44. Endocr Relat Cancer. 2004 Dec;11(4):793-814 - PubMed
  45. Cancer Cell. 2007 Jul;12(1):81-93 - PubMed
  46. Br J Cancer. 2007 Mar 26;96(6):952-9 - PubMed
  47. Cell Biol Int. 2001;25(7):613-20 - PubMed
  48. Adv Cancer Res. 2000;79:1-38 - PubMed
  49. Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8 - PubMed
  50. Mol Cancer Ther. 2006 Nov;5(11):2676-84 - PubMed
  51. Cell Biol Int. 2010 Feb;34(2):171-5 - PubMed
  52. BMC Cancer. 2010 Apr 28;10:168 - PubMed
  53. Oncogene. 2000 May 25;19(23):2739-44 - PubMed
  54. Curr Opin Oncol. 2006 Jan;18(1):77-82 - PubMed
  55. Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 - PubMed
  56. Genes Dev. 2003 Aug 1;17(15):1829-34 - PubMed
  57. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3130-5 - PubMed
  58. Cancer Res. 2003 Jun 1;63(11):2948-56 - PubMed
  59. Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):755-60 - PubMed
  60. Oncogene. 1997 Oct;15(18):2169-77 - PubMed
  61. Cancer Res. 2007 Oct 1;67(19):9304-14 - PubMed
  62. Microbiol Mol Biol Rev. 2005 Mar;69(1):79-100 - PubMed
  63. Int J Cancer. 1997 Jun 11;71(6):1010-8 - PubMed
  64. Nature. 2007 Jul 26;448(7152):439-44 - PubMed
  65. Cancer Res. 2007 Sep 1;67(17):7960-5 - PubMed
  66. Science. 2005 Feb 18;307(5712):1098-101 - PubMed
  67. J Clin Oncol. 2003 May 15;21(10):1980-7 - PubMed
  68. Endocrinology. 2005 Nov;146(11):4609-18 - PubMed

Publication Types